These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 2483884)

  • 1. Humoral immunity to the human immunodeficiency virus.
    Weber J
    Curr Opin Immunol; 1989-1990 Feb; 2(3):420-3. PubMed ID: 2483884
    [No Abstract]   [Full Text] [Related]  

  • 2. HIV/AIDS research. Potent HIV antibodies spark vaccine hopes.
    Cohen J
    Science; 2009 Sep; 325(5945):1195. PubMed ID: 19729632
    [No Abstract]   [Full Text] [Related]  

  • 3. Anti-HIV neutralizing antibodies do not inhibit HIV-induced cell fusion in vitro.
    Emilie D; Delattre RM; Galanaud P; Nicolas JF
    Res Virol; 1991; 142(6):439-42. PubMed ID: 1803411
    [No Abstract]   [Full Text] [Related]  

  • 4. The immunopathogenesis of HIV infection.
    Rosenberg ZF; Fauci AS
    Adv Immunol; 1989; 47():377-431. PubMed ID: 2573256
    [No Abstract]   [Full Text] [Related]  

  • 5. Human immunodeficiency virus (HIV) type 1 strain MN neutralizing antibody in HIV-infected children: correlation with clinical status and prognostic value.
    Robert-Guroff M; Roilides E; Muldoon R; Venzon D; Husson R; Marshall D; Gallo RC; Pizzo PA
    J Infect Dis; 1993 Mar; 167(3):538-46. PubMed ID: 7680059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA vaccines for immunodeficiency viruses.
    Robinson HL
    AIDS; 1997; 11 Suppl A():S109-19. PubMed ID: 9451974
    [No Abstract]   [Full Text] [Related]  

  • 7. HIV vaccines. Magic of the occult?
    Montefiori D; Moore JP
    Science; 1999 Jan; 283(5400):336-7. PubMed ID: 9925493
    [No Abstract]   [Full Text] [Related]  

  • 8. Humoral immune responses to homologous envelope peptides in vaccinees and lab workers infected with HIV.
    Pincus SH; Messer K
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1347. PubMed ID: 1466954
    [No Abstract]   [Full Text] [Related]  

  • 9. How does the HIV escape cytotoxic T cell immunity?
    Phillips RE; McMichael AJ
    Chem Immunol; 1993; 56():150-64. PubMed ID: 7680867
    [No Abstract]   [Full Text] [Related]  

  • 10. Summary of the Antigenic Variation Working Group.
    Bradac J; Ho D
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1419-21. PubMed ID: 1466971
    [No Abstract]   [Full Text] [Related]  

  • 11. Performance evaluation of a new automated fourth-generation HIV Ag/Ab combination chemiluminescence immunoassay.
    Zhao Y; Gou Y; Li D; Wang T; Huang X; Shi M; Tao C
    Clin Chem Lab Med; 2018 Apr; 56(5):e115-e117. PubMed ID: 29320363
    [No Abstract]   [Full Text] [Related]  

  • 12. Challenges and opportunities for development of an AIDS vaccine.
    Nabel GJ
    Nature; 2001 Apr; 410(6831):1002-7. PubMed ID: 11309631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fusion-competent vaccines: broad neutralization of primary isolates of HIV.
    LaCasse RA; Follis KE; Trahey M; Scarborough JD; Littman DR; Nunberg JH
    Science; 1999 Jan; 283(5400):357-62. PubMed ID: 9888845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Yeast-expressed p55 precursor core protein of human immunodeficiency virus type 1 does not elicit protective immunity in chimpanzees.
    Emini EA; Schleif WA; Quintero JC; Conard PG; Eichberg JW; Vlasuk GP; Lehman ED; Polokoff MA; Schaeffer TF; Schultz LD
    AIDS Res Hum Retroviruses; 1990 Nov; 6(11):1247-50. PubMed ID: 2127681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV antibodies and vaccine design.
    Bolognesi DP
    AIDS; 1989; 3 Suppl 1():S111-8. PubMed ID: 2482052
    [No Abstract]   [Full Text] [Related]  

  • 16. Humoral immunity to HIV, SIV, and SHIV.
    Haigwood NL; Zolla-Pazner S
    AIDS; 1998; 12 Suppl A():S121-32. PubMed ID: 9632993
    [No Abstract]   [Full Text] [Related]  

  • 17. A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response.
    Zhang PF; Bouma P; Park EJ; Margolick JB; Robinson JE; Zolla-Pazner S; Flora MN; Quinnan GV
    J Virol; 2002 Jan; 76(2):644-55. PubMed ID: 11752155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV T cell vaccines, the importance of clades.
    McMichael A; Mwau M; Hanke T
    Vaccine; 2002 May; 20(15):1918-21. PubMed ID: 11983245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Broadly reactive antibodies against a gp120 V3 loop multi-epitope polypeptide neutralize different isolates of human immunodeficiency virus type 1 (HIV-1).
    Montero M; Menéndez A; Domínguez MC; Navea L; Vilarubia OL; Quintana D; Izquierdo M; Jiménez V; Reyes O; Lobaina L; Noa E; Duarte CA
    Vaccine; 1997 Aug; 15(11):1200-8. PubMed ID: 9286044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mother-to-child transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies against primary isolates.
    Scarlatti G; Albert J; Rossi P; Hodara V; Biraghi P; Muggiasca L; Fenyö EM
    J Infect Dis; 1993 Jul; 168(1):207-10. PubMed ID: 8515110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.